GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CellaVision AB (OTCPK:CLVSF) » Definitions » EV-to-FCF

CLVSF (CellaVision AB) EV-to-FCF : 34.14 (As of Mar. 24, 2025)


View and export this data going back to 2010. Start your Free Trial

What is CellaVision AB EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, CellaVision AB's Enterprise Value is $391.92 Mil. CellaVision AB's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was $11.48 Mil. Therefore, CellaVision AB's EV-to-FCF for today is 34.14.

The historical rank and industry rank for CellaVision AB's EV-to-FCF or its related term are showing as below:

CLVSF' s EV-to-FCF Range Over the Past 10 Years
Min: 12.93   Med: 70.66   Max: 832.15
Current: 32.56

During the past 13 years, the highest EV-to-FCF of CellaVision AB was 832.15. The lowest was 12.93. And the median was 70.66.

CLVSF's EV-to-FCF is ranked worse than
56.81% of 382 companies
in the Medical Devices & Instruments industry
Industry Median: 27.355 vs CLVSF: 32.56

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-03-24), CellaVision AB's stock price is $19.2796. CellaVision AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $0.559. Therefore, CellaVision AB's PE Ratio (TTM) for today is 34.49.


CellaVision AB EV-to-FCF Historical Data

The historical data trend for CellaVision AB's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CellaVision AB EV-to-FCF Chart

CellaVision AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 196.25 102.94 80.42 45.47 41.97

CellaVision AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 45.47 33.18 32.27 45.18 41.97

Competitive Comparison of CellaVision AB's EV-to-FCF

For the Medical Devices subindustry, CellaVision AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CellaVision AB's EV-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, CellaVision AB's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where CellaVision AB's EV-to-FCF falls into.



CellaVision AB EV-to-FCF Calculation

CellaVision AB's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=391.918/11.479
=34.14

CellaVision AB's current Enterprise Value is $391.92 Mil.
CellaVision AB's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $11.48 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CellaVision AB  (OTCPK:CLVSF) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

CellaVision AB's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=19.2796/0.559
=34.49

CellaVision AB's share price for today is $19.2796.
CellaVision AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.559.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


CellaVision AB EV-to-FCF Related Terms

Thank you for viewing the detailed overview of CellaVision AB's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


CellaVision AB Business Description

Traded in Other Exchanges
Address
Mobilvagen 12, Lund, SWE, 22362
CellaVision AB is engaged in the business of supplying digital solutions for blood and body fluid analysis. Its solutions are based on digital image analysis technology, artificial intelligence, and information technology. The firm's product portfolio consists of CellaVision peripheral blood application, CellaVision advanced RBC application, and CellaVision remote review software. Its customers include mainly large hospital laboratories and commercial laboratories in North America, Europe and China, and Japan. The company derives the majority of its revenue from the sale of analyzers/software.

CellaVision AB Headlines

From GuruFocus

Q3 2024 CellaVision AB Earnings Call Transcript

By GuruFocus News 10-25-2024

Q1 2020 CellaVision AB Earnings Call Transcript

By GuruFocus Research 03-03-2024

Q3 2023 CellaVision AB Earnings Call Transcript

By GuruFocus Research 03-03-2024

Q1 2023 CellaVision AB Earnings Call Transcript

By GuruFocus Research 03-03-2024

Q1 2021 CellaVision AB Earnings Call Transcript

By GuruFocus Research 03-03-2024

Q2 2020 CellaVision AB Earnings Call Transcript

By GuruFocus Research 03-03-2024

Q2 2024 CellaVision AB Earnings Call Transcript

By GuruFocus Research 07-21-2024

Q2 2023 CellaVision AB Earnings Call Transcript

By GuruFocus Research 03-03-2024

Q4 2023 CellaVision AB Earnings Call Transcript

By GuruFocus Research 02-10-2024

3 Scandinavian Companies With Strong Margin Growth

By James Li James Li 12-01-2020